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PERCUTANEOUS AORTIC
VALVE IMPLANTATION: WHAT
DOES OVERSIZING MEAN?
To the Editor:
We read with interest the recent
article by Litzler and colleagues1 in
the Journal of Thoracic and Cardio-
vascular Surgery.The authors reported
their first case of emergency surgical
aortic valve replacement for severe
acute aortic regurgitation after retro-
grade transfemoral Cribier-Edwards
valve implantation.
We would like to comment on this
instructive case report and ask for
some clarifications:
When valved stent implantation is
planned in a patient, accurate pre-
procedural determination of the aortic
annulus size is of crucial importance.
A prosthesis–aortic annulus mismatch
may be responsible for valve migra-
tion or severe paravalvular leak if the
chosen prosthesis is too small and for
coronary obstruction or leaflet distor-
tion if it is too large.2
The incidence of paravalvular leak
has been shown to be dramatically
high in previous studies.3,4 To reduce
the incidence and severity of paravalvu-
lar leak, the oversizing technique (ie, the
choice of a prosthesis size at least 2 mm
more than that of the aortic annulus di-
ameter as determined by transthoracic
echocardiography [TTE]) has been pro-
posed and proved to be effective.4
Nevertheless, several previous stud-
ies have shown that measurement of
the aortic annulus diameter by TTE is
inaccurate when compared with surgi-
cal sizing.5 TTE tends to underesti-
mate by up to 5 mm (3 mm in this
case report) the size of the aortic annu-
lus. In the present case, the chosen size
of the implanted valve was 23 mm.
The latter was supposed to be over-
sized based on the TTEmeasurements.
The surgically implanted valve was
also 23 mm based on the surgical mea-
surements. Despite ‘‘oversizing’’ in
this reported percutaneous valve im-
plantation, severe paravalvular leak
occurred, which means, in a sense,
that this strategy has not solved this
major problem at the present time.
We would like to ask the authors
a few questions:
 What does ‘‘oversizing’’ mean for
them in the choice of the implant-
able valve ? Is oversizing based on
the TTE measurements of the aortic
annulus diameter or is it based on
the ‘‘true’’ aortic annulus diameter
if the latter could be measured?
 Do they still rely on TTE for deter-
mination of the aortic annulus diam-
eter or have they changed their
imaging technique?
 Have they changed the magnitude
of oversizing, based on this reported
experience?
 If so, how effective is their new ap-
proach regarding the occurrence of
paravalvular leak?
Optimal sizing of valved stents
remains a critical issue with many im-
plications on the post-procedural
course. The readers of the Journal
would greatly appreciate the answers
to these ‘‘practical’’ questions from
one of the most experienced teams in
interventional aortic valve therapy.
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OF VISCERAL PLEURAL
INVASION AND TUMOR SIZE IN
NON–SMALL CELL LUNG
CANCER
To the Editor:
We read with great interest the article
byShimizu and colleagues1 published in
the July 2005 issue of the Journal. They
found that visceral pleural invasion
(VPI) is a significant poor prognostic
factor of non–small cell lung cancer
(NSCLC), regardless of N status. Stage
I NSCLC has been subdivided into IA
(T1N0M0) and IB (T2N0M0) based on
tumor size (3 cm as a cutoff value) and
non–size-based T2 descriptors (includ-
ingVPI, hilar atelectasis, andobstructive
pneumonitis).2 Although a poor prog-
nostic effect of VPI has generally been
reported, its prognostic value for
survival has remained controversial.3,4
SERUM BRAIN NATRIURETIC
PEPTIDE FOR PREDICTION OF
SUCCESSFUL MEDICAL
TREATMENT OF PATENT
DUCTUS ARTERIOSUS IN
PREMATURE INFANTS
To the Editor:
Wereadwith great interest the report
by Tschuppert and colleagues1 entitled
‘‘The Effect of Ductal Diameter on
Surgical andMedical Closure of Patent
Ductus Arteriosus in Preterm Neo-
nates: Size Matters’’ and the relevant
letter by Giardini and colleagues.2
Although Tschuppert and col-
leagues suggested that the size of
a patent ductus arteriosus (PDA) can
be used to predict patients in whom
medical management is likely to fail
to achieve hemodynamic irrelevance,
Giardini and colleagues claimed that
the difference in PDA diameter in pa-
tients who did and did not respond to
medical treatment was extremely low
and questioned how such a small dif-
ference can be clinically significant.2
We would like to add some com-
ment regarding factors other than
PDA size to predict successful medical
treatment according to our pilot study.
Recent reports suggesting that se-
rum brain natriuretic peptide (sBNP)
levels are parallel to the severity of
PDA3-5 prompted us to investigate
the relationship between the dose of
indomethacin and the levels of sBNP
or maximum diameter of PDA by
ultrasound cardiography (USCG)
during the first week of life. Indometh-
acin was repeatedly (1–4 times) ad-
ministered intravenously at a single
dose of 0.1 to 0.2 mg/kg until the clo-
sure of the PDA was confirmed by
USCG. sBNPwas measured by a com-
mercially available kit using fluores-
cent immunoassay (‘‘Shiono-Spot,’’
Shionogi Pharmaceutical Co, Osaka,
Japan). The required blood volume is
only 70 mL, and a result can be ob-
tained within 15 minutes with this kit.
There was a significant relationship
between the peak levels of sBNP
within 5 days of life and the total
dose of indomethacin (n ¼ 8, r ¼
0.78, P< .05, Table). Notably, the re-
quired total dose of indomethacin to
close a symptomatic PDA was 0.1 to
0.2 mg/kg in the infants with sBNP
levels less than 1000 pg/mL, whereas
the required dose was 0.3 mg/kg or
more in those with higher sBNP levels
(>2000 pg/mL), as shown in Table 1.
TABLE 1. Relationship among serum levels of brain natriuretic peptide, size of patent ductus
arteriosus, and total dose of indomethacin
Case no.
Gestational
age (wk)
Total dose of
indomethacin (mg/kg)
Age at PDA
closure* (d)
Peak levelsy of
sBNP (pg/mL)
Maximum
diameter of
PDA (mm)
1 27.7 0.1 5 640.4 1.5
2 27.7 0.2 8 40.9 1.2
3 31.4 0.2 3 83.2 1.4
4 28.0 0.2 3 796.5 1.5
5 28.7 0.2 3 152.3 2.1
6 28.7 0.3 16 >2000 2.1
7 29.9 0.6 5 >2000 3.9
8z 29.9 0.7 14 >2000 3.3
PDA, Patent ductus arteriosus; sBNP, serum brain natriuretic peptide. *Confirmed by ultrasound echocardiography.
yMeasured within 5 days of life. zPDA reopened at the age of 16 days and received surgical ligation.
Letters to the EditorShimizu and colleagues1 have dem-
onstrated that both VPI and tumor size
had a significant impact on survival for
patients with NSCLC in univariate anal-
ysis. However, tumor size failed to be
a predictor of survival in multivariate
analysis, whereasVPI was still a signifi-
cant predictor for all patients with
NSCLC (P<.001) and those with stage
I disease (P¼ .0104).VPI overwhelmed
tumor size as a prognostic factor for
NSCLC in their study. However, most
studies in the literature have reported tu-
mor size as a significant prognostic fac-
tor in NSCLC. The International
Association for the Study of Lung Can-
cer Lung Cancer Staging Project Com-
mittee has recommended that T1
tumors be classified as T1a (2 cm)
and T1b (>2 to 3 cm) and that T2
tumors be classified as T2a (>3 to
5 cm), T2b (>5 to 7 cm), and T3
(>7 cm).5 However, revision of non–
size-based T2 descriptors has not been
recommended because of the small
number of patients, inconsistent clinical
and pathologic results, or lack of valida-
tion.5 Their proposal emphasized the
prognostic value of tumor size in
NSCLC. Shimizu and colleagues1
have also demonstrated that VPI was
significantly associated with tumor
size. We wonder how the authors dealt
with the interaction of the 2 variables
in multivariate analysis and interpreted
the greater effect of VPI on survival in
their study.
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